Kathryn Mngadi

University of South Africa — South Africa

Medicine · Health Sciences

17h-index1.3kcitations54works12.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS Research and Interventions(22), HIV Research and Treatment(21), Vaccine Coverage and Hesitancy(12), Adolescent Sexual and Reproductive Health(9), SARS-CoV-2 and COVID-19 Research(7)

Publications52 total

No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCT
Frontiers in Immunology·2025Open Access
Corrigendum to ‘Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study’. EBioMedicine 2024;108: 105320
EBioMedicine·2025Open Access
Pregnancy and contraceptive use among participants of childbearing potential in the HVTN 705 HIV vaccine trial in Southern Africa
Frontiers in Reproductive Health·2025Open Access
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines
Frontiers in Immunology·2025· 2 citedOpen Access
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Emerging Microbes & Infections·2025· 1 citedOpen Access
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
UNC Libraries·2025Open Access
Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
EClinicalMedicine·2025· 5 citedOpen Access
Randomised Trial of a Single Dose of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN in Previously Vaccinated and Unvaccinated Adults Living with and without HIV in South Africa: Safety and Immunogenicity
SSRN Electronic Journal·2025Open Access
Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study
PLOS Global Public Health·2024· 3 citedOpen Access
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial
PLOS Global Public Health·2024Open Access
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study
EBioMedicine·2024· 13 citedOpen Access
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial
The Lancet Infectious Diseases·2024· 29 citedOpen Access
Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study
2024· 1 citedOpen Access
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
PLoS Medicine·2024· 8 citedOpen Access
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Clinical Infectious Diseases·2024· 136 citedOpen Access
Hybrid Versus Vaccine Immunity of mRNA-1273 Among People Living with HIV in East and Southern Africa: The Multicentre, Open-Label COVPN 3008 (Ubuntu) Clinical Trial
SSRN Electronic Journal·2024Open Access
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials
UNC Libraries·2023Open Access
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
UNC Libraries·2023Open Access
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions
Clinical Infectious Diseases·2023· 46 citedOpen Access
High Asymptomatic Carriage With the Omicron Variant in South Africa
Clinical Infectious Diseases·2022· 81 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Lawrence Corey(19), Linda‐Gail Bekker(18), Craig Innes(15), Peter B. Gilbert(15), Glenda Gray(14), Fatima Laher(14), M. Juliana McElrath(13), James G. Kublin(13), Nigel Garrett(12), Nyaradzo Mgodi(11), John Hural(10), William Brumskine(10), Georgia D. Tomaras(9), Katherine Gill(9), Leila E. Mansoor(9), Michal Juraska(9), Zoe Moodie(8), Mookho Malahleha(8), Maphoshane Nchabeleng(8), Erica Andersen‐Nissen(8)